



Universiteit
Leiden
The Netherlands

Quantitative lateral flow strip assays as user-friendly tools to detect biomarker profiles for leprosy

Hooij, A. van; Fat, E.M.T.K.; Richardus, R.; Eeden, S.J.F. van den; Wilson, L.; Dood, C.J. de; ... ; Geluk, A.

Citation

Hooij, A. van, Fat, E. M. T. K., Richardus, R., Eeden, S. J. F. van den, Wilson, L., Dood, C. J. de, ... Geluk, A. (2016). Quantitative lateral flow strip assays as user-friendly tools to detect biomarker profiles for leprosy. *Scientific Reports*, 6. doi:10.1038/srep34260

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/4256764>

Note: To cite this publication please use the final published version (if applicable).

SCIENTIFIC REPORTS

OPEN

Quantitative lateral flow strip assays as User-Friendly Tools To Detect Biomarker Profiles For Leprosy

Received: 14 July 2016
Accepted: 08 September 2016
Published: 29 September 2016

Anouk van Hooij¹, Elisa M. Tjon Kon Fat², Renate Richardus³, Susan J. F. van den Eeden¹, Louis Wilson¹, Claudia J. de Dood², Roel Faber³, Korshed Alam⁴, Jan Hendrik Richardus³, Paul L. A. M. Corstjens² & Annemieke Geluk¹

Leprosy is a debilitating, infectious disease caused by *Mycobacterium leprae*. Despite the availability of multidrug therapy, transmission is unrelenting. Thus, early identification of *M. leprae* infection is essential to reduce transmission. The immune response to *M. leprae* is determined by host genetics, resulting in paucibacillary (PB) and multibacillary (MB) leprosy associated with dominant cellular or humoral immunity, respectively. This spectral pathology of leprosy compels detection of immunity to *M. leprae* to be based on multiple, diverse biomarkers. In this study we have applied quantitative user friendly lateral flow assays (LFAs) for four immune markers (anti-PGL-I antibodies, IL-10, CCL4 and IP-10) for whole blood samples from a longitudinal BCG vaccination field-trial in Bangladesh. Different biomarker profiles, in contrast to single markers, distinguished *M. leprae* infected from non-infected test groups, patients from household contacts (HHC) and endemic controls (EC), or MB from PB patients. The test protocol presented in this study merging detection of innate, adaptive cellular as well as humoral immunity, thus provides a convenient tool to measure specific biomarker profiles for *M. leprae* infection and leprosy utilizing a field-friendly technology.

Leprosy, a chronic infectious disease caused by *Mycobacterium leprae* (*M. leprae*) ranking second as the most pathogenic mycobacterial infectious disease after tuberculosis (TB), is still considered a major threat in developing countries¹. The condition is characterized by skin lesions and damage to peripheral nerves, the hallmark of leprosy pathology often resulting in severe, life-long disabilities and associated stigma^{2,3}.

Despite the remarkable decrease in prevalence following introduction of multidrug therapy, it remains challenging to further reduce transmission as substantiated by the stable global annual incidence around 200,000 new cases for the past 10 years⁴. This continued transmission is largely due to *M. leprae* infected individuals lacking clinical symptoms⁵. In addition, identification of host-derived biomarkers for progression to disease is complicated by the low incidence and long incubation time requiring extensive, longitudinal studies. Furthermore, although molecular techniques to elicit strain differences within the leprosy bacillus are important diagnostic tools to enhance our understanding of the epidemiology of leprosy, differentiate between relapse and re-infection^{6–10}, these pathogen-derived profiles are not suitable to indicate development of leprosy in infected, asymptomatic individuals.

These hurdles contributed to the current lack of tests for detection of asymptomatic *M. leprae* infection and diagnosis of early stage leprosy¹¹. As clinical resistance to commonly used antibiotics in leprosy treatment is increasingly occurring^{12,13}, such tests should be highly specific to prevent redundant use of antibiotics.

Clinical manifestations closely parallel cellular immunity to *M. leprae* such that leprosy presents as a characteristic spectrum ranging from tuberculoid (TT) or paucibacillary (PB) leprosy to lepromatous (LL) or multibacillary (MB) leprosy¹⁴. TT patients in general show strong T helper 1 cell (Th1) immunity with exacerbated

¹Dept. of Infectious Diseases, Leiden University Medical Center, The Netherlands. ²Dept. Molecular Cell Biology, Leiden University Medical Center, The Netherlands. ³Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁴Rural Health Program, The Leprosy Mission International Bangladesh, Nilphamari, Bangladesh. Correspondence and requests for materials should be addressed to A.G. (email: a.geluk@lumc.nl)

levels of pro-inflammatory cytokines and develop localized granulomatous disease with bacilli scarcely detectable in their lesions. At the opposite pole of the spectrum are LL patients who predominantly generate Th2 and anti-inflammatory cytokines such as interleukin-10 (IL-10) resulting in disseminating, progressive infections¹⁵. In between these two opposite poles of the leprosy spectrum, borderline states of leprosy [borderline tuberculoid (BT), borderline (BB) and borderline lepromatous (BL)] are positioned. Due to the diverse disease spectrum, detection of *M. leprae* infection in diagnostic tests requires multiple, diverse biomarkers specific for both cellular and humoral mediated immunity. In previous studies we have shown that IFN- γ -inducible protein 10 (IP-10) in response to a *M. leprae*-specific antigen (ML2478) correlates with *M. leprae* exposure and thereby the risk of infection and its subsequent transmission¹⁶. Additionally, we demonstrated that chemokine (C-C motif) ligand 4 (CCL4), a component of the innate immunity, can be used to identify pathogenic immunity against *M. leprae* since it was increased in patients, partly in household contacts but not in endemic controls¹⁶. IL-10, on the other hand, is associated with suppression of Th1 cells in leprosy^{17–19}. Moreover, most lepromatous patients with high bacillary loads produce antibodies against the *M. leprae* specific phenolic glycolipid I (PGL-I)^{20,21}, which are hardly detected in PB²². Hence, sensitive tests that can simultaneously quantitate multiple analytes in one sample provide apt tools to characterize different clinical leprosy types. In particular, tests based on multicomponent host biomarker profiles that can identify *M. leprae* infected individuals (yet) without clinical symptoms of leprosy, will be useful for guidance of prophylactic treatment, thereby contributing to reduction of *M. leprae* transmission as well as prevention of disabilities.

Inherent to the situation in leprosy endemic areas is the absence of sophisticated laboratories. It is therefore imperative that new diagnostic tests are facilitated for application in the field. Up-converting phosphor lateral flow assays (UCP-LFAs) have previously shown to be robust, low-complexity assays, representing a field-friendly alternative for common laboratory-based ELISAs^{23,24}, applicable for detection of multiple pathogens including food-borne pathogenic strains and potential biowarfare/bioterrorism agents^{25–27}. Field evaluation of UCP-LFAs for detection of IL-10, IP-10, CCL4 and anti-PGL-I IgM demonstrated high correlation with ELISAs using samples from cohorts of limited numbers of leprosy- or TB patients^{28,29}.

In the current study UCP-LFAs were applied to a more extensive (five-fold) sample size compared to our previous studies, derived from a randomized BCG vaccination field trial in Bangladesh³⁰. Six test groups were included: MB patients, PB patients, healthy household contacts (HHC), HHC vaccinated with Bacillus Calmette-Guérin (BCG) (HHC&BCG), HHC who developed leprosy after BCG vaccination (new cases; NC) and endemic controls (EC) from the same area without known contact with leprosy patients. This extended cohort study allowed exploratory identification of biomarker profiles for *M. leprae* infection, leprosy disease per se, the type of leprosy and BCG vaccination as determined with UCP-LFAs for the above indicated targets.

Results

Performance of the UCP-LFA versus ELISA. Whole blood samples ($n = 726$) from all individuals were analysed using ELISA, as well as the field-friendly UCP-LFAs for IL-10, IP-10, CCL4 and anti-PGL-I antibodies. Comparison of UCP-LFA and ELISA results demonstrated significant correlation for all four biomarkers ($p < 0.0001$), confirming earlier observations^{28,29}.

The diagnostic performance of the UCP-LFA in comparison to ELISA was further assessed through AUCs for the two most distinct phenotypes: MB patients ($n = 34$) and EC ($n = 51$). IL-10, IP-10 and CCL4 levels were determined in Nil, WCS and Mlep samples, as well as anti-PGL-I IgM levels (Fig. 1). The IL-10 and IP-10 UCP-LFAs outperformed the corresponding ELISAs, whereas the CCL4 and anti-PGL-I IgM tests performed equally. For discrimination of MB patients from EC, the proposed diagnostic field-tool UCP-LFA provides an equally well or even better alternative for the conventional ELISAs.

***M. leprae* specific responses based on single analyte UCP-LFA measurements.** In order to put the quantitative test results obtained with the four single UCP-LFAs in the context of their biomarker potential, we assessed each analyte/stimulus combination by comparing median group levels. As indicated by the AUCs in Fig. 1, MB patients can be distinguished from EC based on IP-10 and CCL4 (irrespective of stimulus), anti-PGL-I IgM and IL-10_{WCS}, therefore also showing significantly different median levels (Fig. 2, Table 1). Moreover, median levels of anti-PGL-I IgM and IP-10_{Nil} differed between MB patients and (BCG-vaccinated) HHC, whereas median levels of IP-10_{WCS} and CCL4_{WCS} only distinguished the non-vaccinated HHC from MB patients. BCG vaccination therefore affects the immune response in HHC, as reflected by the significant difference in IP-10_{WCS} levels between HHC and HHC&BCG ($p = 0.018$) (Fig. 2b). Furthermore, IL-10_{WCS} levels differed between HHC and EC, while median levels of IP-10_{WCS} and CCL4_{WCS} differed between HHC&BCG and EC as well. PB patients and EC showed significantly different median CCL4_{Nil} and CCL4_{WCS} levels (Fig. 2c), as well as borderline significant different levels for IL-10_{WCS} ($p = 0.07$) and IP-10_{WCS} ($p = 0.06$).

The ability of each analyte/stimulus combination to distinguish between two groups is summarized in Table 1, thereby reviewing the biomarker potential of the four individual host immune markers. Remarkably, the levels of IP-10 ($p < 0.0001$), IL-10 ($p = 0.003$) and CCL4 ($p < 0.0001$) in WCS stimulated samples were more significantly different for MB and EC than anti-PGL-I IgM levels ($p = 0.0042$). Moreover, anti-PGL-I IgM levels could not be used to discriminate PB patients or (BCG-vaccinated) HHC from EC, which clearly demonstrates the added value of IP-10, IL-10 and CCL4 in leprosy diagnostics.

Biomarker signatures to specify *M. leprae* infection, leprosy or disease classification. Diagnostic tests that allow detection of *M. leprae* infection, leprosy per se and leprosy classification would be of great benefit to the general healthcare in leprosy endemic areas. The four host immune markers allowed distinction between two groups (Table 1). However, to distinguish *M. leprae* infected from non-infected individuals or patients from healthy contacts, we compared host immune markers for multiple groups (Fig. 3).




Figure 1. Discriminatory capacity of ELISA and UCP-LFA. To compare the ability of ELISA (dotted line) and UCP-LFA (solid line) to discriminate between individuals with or without disease ROC curves were computed using data of MB patients and EC. Areas under the curve (AUCs) were compared for all 10 conditions tested, shown in the lower right corner of each graph. **(a)** ROC curves for IP-10 stimulated and unstimulated samples based on concentration in pg/ml, showing an improved AUC for the UCP-LFA for IP-10_{Nil} and IP-10_{WCS}. **(b)** ROC curves for IL-10 stimulated and unstimulated samples based on concentration in pg/ml, showing an improved (IL-10_{Nil}) or equal AUC for UCP-LFA. **(c)** ROC curves for CCL4 stimulated and unstimulated samples based on concentration in pg/ml, showing comparable values for UCP-LFA and ELISA. **(d)** ROC curves for anti-PGL-I IgM in unstimulated samples based on ratio, showing comparable AUCs for ELISA and UCP-LFA.




Figure 2. Identification of *M. leprae* specific IL-10, IP-10, CCL4 and anti-PGL-I IgM antibodies by UCP-LFA. (a) IL-10 concentrations (pg/ml) measured per group per stimulus show that MB patients, HHC and BCG-vaccinated HHC significantly differ from EC upon WCS stimulation. (b) IP-10 concentrations (pg/ml) measured per group per stimulus show that MB patients significantly differ from EC in both stimulated and unstimulated samples, from HHC in unstimulated and WCS stimulated samples and from BCG vaccinated HHC in unstimulated samples. BCG vaccinated HHC significantly differ from HHC and EC upon WCS stimulation. (c) CCL4 concentrations (pg/ml) measured per group, per stimulus show that MB patients significantly differ from EC in both stimulated and unstimulated samples and from HHC in WCS stimulated samples. PB patients significantly differ from EC in unstimulated and WCS stimulated samples and BCG vaccinated HHC significantly differ from EC in WCS stimulated samples. (d) anti-PGL-I IgM ratio measured per groups shows that MB patients have significantly higher levels of anti-PGL-I IgM compared to HHC, BCG vaccinated HHC and EC. P-values: * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$.

	MB vs HHC	MB vs HHC&BCG	MB vs EC	PB vs EC	HHC vs EC	HHC&BCG vs EC	HHC&BCG vs HHC
anti-PGL-I IgM	++	++	++	—	—	—	—
IP-10	++	++	++	—	—	—	—
IP-10 WCS	++++	—	++++	—	—	++	+
IP-10 <i>M. leprae</i> proteins	—	—	+	—	—	—	—
IL-10	—	—	—	—	—	—	—
IL-10 WCS	—	—	+++	—	++	+	—
IL-10 <i>M. leprae</i> proteins	—	—	—	—	—	—	—
CCL4	—	—	+	+	—	—	—
CCL4 WCS	++	—	++++	+	—	++	—
CCL4 <i>M. leprae</i> proteins	—	—	+	—	—	—	—

Table 1. Discriminatory biomarkers with potential for leprosy diagnostics. Differences in IP-10, IL-10, CCL4 and anti-PGL-I IgM levels between various test groups detected by UCP-LFA are provided. Each row represents one of the 10 different analyte/stimulus combinations measured. Each column shows the potential to distinguish the test groups indicated, only displaying the groups for which significant differences were observed: $-p \geq 0.05$ indicates inability to distinguish test groups, $+p \leq 0.05$, $++p \leq 0.01$, $+++p \leq 0.001$, $++++p \leq 0.0001$ indicating increasing capacity to distinguish test groups. Using one or multiple analyte/stimulus combination MB patients could be distinguished from (BCG-vaccinated) HHC and EC, whereas PB patients and BCG-vaccinated HHC could be distinguished from EC.

a

	Groups to differentiate	Potential Profile
Infection	MB, PB, HHC, HHC&BCG vs. EC	IP10 _{Mlep} , CCL4 _{WCS} , IL10 _{WCS}
Disease per se	MB, PB vs. HHC, HHC&BCG, EC	IP10 _{WCS} , CCL4 _{WCS}
Disease classification	MB vs. PB	anti-PGL-I IgM, IL10 _{WCS} , IP10 _{Nal}

b




Figure 3. Positive test results per analyte/stimulus combination used to construct potential biomarker profiles. The groups that should be differentiated to indicate *M. leprae* infection, disease per se and disease classification are shown. The potential profiles indicated are based on the percentage of positive individuals of these particular groups. The cut-off for positivity was based on values for NEC (Supplementary Table S3) per analyte/stimulus combination the percentage of individuals with a positive test result per group is shown. Based on these data the optimal analyte/stimulus combination to differentiate either infected from non-infected groups, patients and non-patients groups or MB and PB patients were selected to construct the potential profiles described.

First, in order to combine immune markers into multicomponent host biomarker profiles, positive UCP-LFA results for each analyte/stimulus combination were collectively specified (Fig. 3; Supplementary Table S3). Second, analyte/stimulus combinations were selected such that they optimally distinguished individuals with a specified disease- or infection state (Fig. 3), considering all HHC as *M. leprae* infected. This resulted in three specific profiles:

- (I) To indicate *M. leprae* infection we selected single test results obtained with IP-10_{Mlep}, CCL4_{WCS} and IL-10_{WCS} UCP-LFAs as these analyte/stimulus combinations individually showed the least positive test results for EC compared to the *M. leprae* infected test groups (MB, PB, HHC and HHC&BCG) (Fig. 3). The combination of IP-10_{Mlep}, CCL4_{WCS} and IL-10_{WCS} indeed was more frequently positive for MB/PB patients and (BCG-vaccinated) HHC than EC (Fig. 4a). Moreover, AUCs confirmed discrimination between non-infected and *M. leprae* infected test groups based on this multicomponent host immune profile (AUCs: 0.84 (MB vs. EC), 0.75 (PB vs. EC), 0.7 (HHC vs. EC) and 0.71 (HHC&BCG vs. EC) (Supplementary Table S4A).




Figure 4. Potential of biomarker profiles to indicate *M. leprae* infection, disease per se and disease classification. The amount of positive test results per group is shown. (a) IP-10_{Mlep}, CCL4_{WCS} and IL-10_{WCS} significantly differed in MB/PB patients and (BCG-vaccinated) HHC from EC, showing more positive test results in the groups that are exposed to *M. leprae* and thereby indicating *M. leprae* infection. (b) CCL4_{WCS} and IP-10_{WCS} enabled the distinction between patients and HHC, thereby indicating the pathogenic immune responses to *M. leprae* in patients. (c) Anti-PGL-I IgM, IL-10_{WCS} and IP-10_{Nil} showed more positive test results in MB patients thereby enabling the distinction between MB and PB patients. (d) A four marker profile of IL-10_{WCS}, IP-10_{Mlep}, CCL4_{WCS} and anti-PGL-I IgM shows the majority of significant differences observed in A, B and C. P-values: * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$.

- (II) To detect leprosy patients from healthy, though possibly *M. leprae* infected individuals, CCL4_{WCS} and IP-10_{WCS} were selected as immune markers since these single tests were more frequently positive in patients (MB and PB) compared to contacts (HCC and HCC&BCG) and are therefore associated with pathogenic immunity to *M. leprae*. The combination of CCL4_{WCS} and IP-10_{WCS} indeed demonstrated a positive test result more often in patients than in HHC or EC (Fig. 4b), whereas the related AUCs were ≥ 0.66 thus confirming leprosy disease-specificity (Supplementary Table S4B).
- (III) For classification of leprosy a signature consisting of anti-PGL-I IgM, IL-10_{WCS} and IP-10_{Nil} was applied, as each of these markers individually showed more positive test results in MB patients compared to PB patients (Fig. 3). This profile proved to be specific for MB patients (Fig. 4c) and thereby allowed the differentiation of MB and PB patients (AUC = 0.73, Supplementary Table S4C).

Ideally only one multicomponent host biomarker profile for diagnosis of *M. leprae* infection, leprosy per se and leprosy classification would be more suitable for field-use. In this exploratory study, a 4 marker profile of IL-10_{WCS}, IP-10_{Mlep}, CCL4_{WCS} and anti-PGL-I IgM was selected for this purpose, enabling distinction of infected and non-infected individuals by IL-10_{WCS}, IP-10_{Mlep} and CCL4_{WCS}, MB and PB patients from HHC and EC by CCL4_{WCS} and MB from PB patients by anti-PGL-I IgM and IL-10_{WCS} (Fig. 4d; Supplementary Table S4D). However, to distinguish MB from PB patients or PB patients from HHC profile III for leprosy classification showed a higher AUC compared to the 4 marker profile (0.73 vs. 0.65 and 0.66 vs. 0.62 respectively, Supplementary Table S4). These data indicate the importance of distinct phase-specific profiles, the application of which will depend on the nature of the diagnosis to be made.

Nonetheless, application of the 4 marker profile demonstrated the influence of multicomponent host biomarker profiles on test accuracy, showing increased AUCs compared to individual markers (Supplementary Figure S1). The added value of using various analytes indicates the potential of multicomponent host biomarker profiles for leprosy diagnostics to detect *M. leprae* infection, leprosy disease or disease classification.

Discussion

The obvious incessant transmission of *M. leprae* has brought about increased focus in leprosy research on discovery of biomarkers to improve diagnosis. Nevertheless, thus far only few biomarkers for leprosy are recommended

by expert panels¹¹. Consequently, there is a growing need for new and sensitive diagnostic tools based on specific biomarkers which should, ideally, allow straightforward translation into field-friendly tests.

In this exploratory study, we aimed to provide several multicomponent host immune-biomarker profiles which distinguish between distinct stages of *M. leprae* infection. In this process we also emphasized the challenges that need to be tackled to allow application of these biomarkers in the field. As high-tech laboratories are often lacking in leprosy endemic areas, we examined the diagnostic potential of earlier developed field-friendly UCP-LFAs for detection of anti-PGL-I IgM antibodies and cyto/chemokines IP-10, IL-10 and CCL4^{24,28,31}, in an extensive cohort in Bangladesh.

We demonstrated the biomarker potential of IP-10, IL-10, CCL4 and anti-PGL-I IgM measured by UCP-LFAs in whole blood, either in response to *M. leprae* specific stimuli or without stimulus. Moreover, multicomponent host biomarker profiles including selected analyte/stimulus combinations could indicate *M. leprae* infection, leprosy per se or be used for classification of leprosy subtypes. A biomarker profile of IP-10_{Mlep}, CCL4_{WCS} and IL-10_{WCS} was highly indicative of *M. leprae* infection, consistent with our previous finding that the IP-10 response to *M. leprae* specific proteins indicates exposure to *M. leprae*^{16,32}.

Leprosy per se, on the other hand, was indicated by CCL4_{WCS} and IP-10_{WCS}, showing the potential to identify pathogenic immunity against *M. leprae* and confirming earlier observations on CCL4¹⁶. As current diagnostic assays for leprosy are antibody-based and only facilitate the diagnosis of MB cases^{33–35}, inclusion of the host immune markers CCL4 and IP-10 in the profile shows promise for diagnosis of PB patients and indicates the importance of measuring cellular markers simultaneously with humoral markers.

For leprosy classification, the combination of anti-PGL-I IgM, IL-10_{WCS} and IP-10_{Nil} was indicative for MB patients, enabling the distinction between MB and PB patients. Although IL-10 and particularly anti-PGL-I IgM have been identified as characteristic markers for MB leprosy^{36,37}, we also identified IP-10 as a, seemingly counterintuitive, host immune marker for patients at this side of the spectrum who usually display decreased pro-inflammatory immunity. However, since T-cells are not the exclusive source of IP-10³⁸, IP-10 may still be produced in MB patients by monocytes and neutrophils³⁹, as described for HIV-infected TB patients⁴⁰.

To detect *M. leprae* infection, leprosy per se, as well as leprosy classification simultaneously with only one biomarker profile, IL-10_{WCS}, IP-10_{Mlep}, CCL4_{WCS} and anti-PGL-I IgM demonstrated the most optimal 4 marker profile performance. However, it performed less optimal for the distinct stages of *M. leprae* infection than the phase-specific profiles. Other cyto-/chemokines to identify pathogenic immunity to *M. leprae* (e.g. MCP-1 and IL-1³¹⁶), leprosy classification (e.g. CCL17 and CCL18⁴¹) or general mycobacterial infection (EN-RAGE^{42,43}) could therefore be included to achieve more optimal diagnostic accuracy⁴⁴ as distinct phase-specific profiles. In a multiplex UCP-LFA format multicomponent host immune biomarker profiles can be measured in one single test. This format therefore provides a field-friendly diagnostic tool, facilitating the diagnosis of leprosy based on biomarker signatures.

Of note is the observation that CCL4 levels in response to *M. leprae* WCS were elevated for HHC who received BCG vaccination compared to those who did not. Thus, BCG vaccination may also cause increased pro-inflammatory immune responses which renders contacts more prone to development of over-reactive, pathogenic immunity to *M. leprae*. Indeed, in a recent vaccination study an unexpectedly high proportion of HHC presented with PB leprosy after BCG vaccination supporting this idea⁴⁵. In this respect, this vaccination study also shows the importance of immunomonitoring individuals at high risk to identify and treat patients at an early stage. In addition, since BCG vaccination or boost is a well-accepted prophylaxis against leprosy in contacts of newly diagnosed patients⁴⁶, it is relevant to distinguish BCG-induced immunity in healthy contacts from early stage leprosy in these individuals. To efficiently monitor contacts for this purpose, the different stages of infection and disease of leprosy should be covered in diagnostics tools. Through simultaneous measurement of all analytes of interest on a single lateral flow strip, this format allows assessment of multicomponent host biomarker profiles using a unique field-friendly technology^{24,29,31}. Thereby, the UCP-LFA format not only provides diagnostic tools for leprosy but similarly holds promise for TB diagnosis²⁸ and immunomonitoring of other chronic diseases³¹.

Materials and Methods

Study participants. Participants were recruited on a voluntary basis between January 2013 and December 2014 in leprosy endemic areas in Bangladesh as described previously³⁰. Leprosy was diagnosed based on clinical, bacteriological and histological observations and classified by skin smears according to Ridley and Jopling¹⁴. Clinical and demographic data was collected in a database. Participants were classified into six test groups; MB patients, PB patients, HHC, HHC&BCG, NC and EC. Control individuals from the same leprosy endemic area (EC) were examined for the absence of clinical signs and symptoms of leprosy and TB; staff of leprosy- or TB clinics were excluded.

Test group selection. A randomized sample selection was taken from 1110 participants³⁰. Individuals were randomly assigned for sample inclusion using the RAND formula (Excel 2010), aiming for a 50/50 male/female ratio and a 1:1:1 ratio of three age groups: 0–14, 15–29, and 30+ (Supplementary Table S1). In total 242 individuals were selected; MB patients (n = 34), PB patients (n = 45), HHC (n = 54), HHC&BCG (n = 50), EC (n = 51) and NC (n = 8; PB = 7, MB = 1). Patient characteristics are shown in Supplementary Table S2.

Leprosy prevalence. During this study the prevalence in the four districts (Nilphamari, Rongpur, Ponchagor en Thakurganch) was 0.82 per 10,000 with a new case detection rate of 0.98 per 10,000 (monthly report of Rural Health Program of 4 districts of Nilphamari, Bangladesh).

Whole blood assay (WBA). Upon recruitment venous, heparinized blood (4 ml) was used directly in whole blood assays (WBA), using microtubes pre-coated with *M. leprae* whole cell sonicate (designated WCS), ML2478/ML0840 recombinant proteins (designated Mlep)¹⁶ or without antigen stimulus (designated Nil)³⁰. After 24 hour incubation at 37 °C materials were frozen at −20 °C, shipped on dry ice to the LUMC and stored at −80 °C until analysis by ELISA or UCP-LFA²⁴.

PGL-I and *M. leprae* whole cell sonicate (WCS). Synthesized disaccharide epitope (3,6-di-O-methyl-β-D-glucopyranosyl(1 → 4)2,3-di-O-methylrhampyranoside), similar to *M. leprae* specific PGL-I glycolipid, coupled to human serum albumin (synthetic PGL-I; designated ND-O-HSA) and *M. leprae* whole cell sonicate (WCS) generated with support from the NIH/NIAID Leprosy Contract N01-AI-25469 were obtained through the Biodefense and Emerging Infections Research Resources Repository (<http://www.beiresources.org/TBVTMRResearchMaterials/tabid/1431/Default.aspx>)⁴⁷.

PGL-I ELISA. IgM antibodies against *M. leprae* PGL-I were detected as previously described¹⁹. Absorbance of horseradish peroxidase (HRP) was determined at a wavelength of 450 nm.

ELISA for IL-10, IP-10 and CCL4. IP-10 (851.870.015, Diaclone Research, Besancon, France), IL-10 (851.540.015, Diaclone Research, Besancon, France) and CCL4 (DY271-05, R&D systems, Minneapolis, USA) ELISA kits were used. ELISA testing was performed according to the manufacturer's protocol using coating antibody clones B-S10, B-C50 and #24006 and detection antibodies B-T10, BC-55 and BAF271 respectively for IL-10, IP-10 and CCL4. HRP absorbance was determined at wavelength of 450 nm.

UCP-LFA for IL-10, IP-10 and CCL4. UCP-LFAs for CCL4, IL-10 and IP-10 were prepared and performed as described previously^{24,28,29}. The same antibody pairs as used for ELISAs were applied, with the non-biotinylated variant of the detection antibodies (non-biotinylated CCL4: AF-271-NA). Briefly, mixtures of 100 ng cytokine-specific UCP reporter conjugate and diluted serum sample (1:4 for IL-10, 1:30 for IP-10 and 1:300 for CCL4) were incubated for 60 min on a thermoshaker at 37 °C and 900 rpm. The mixture was then applied to cytokine-specific LF strips (containing a Test line with an antibody complementary to the antibody on the UCP particles) and immunochromatography was allowed to continue until strips were dry. LF strips were scanned in a Packard FluoroCount microtiterplate reader adapted for measurement of the UCP label (980 nm IR excitation, 550 nm emission). Results are displayed as the ratio value between Test and Flow-Control signal based on relative fluorescence units (RFUs) measured at the respective lines⁴⁸. Ratio values were translated to concentration based on standard curves for each immunemarker. Lower limit of detection was 32 pg/ml for IL-10 and 316 pg/ml for IP-10 and CCL4.

To determine test positivity, similar wholeblood samples from a set of healthy, non-endemic control individuals (NEC) were analysed and UCP-LFA thresholds were calculated based on the average value of all NEC samples (Supplementary Table S3).

UCP-LFA for anti-PGL-I antibody. For detection of anti-PGL-I IgM antibodies, the same protocol as used for cytokine detection was applied utilizing 100-fold diluted serum and IgM-specific UCP conjugate (UCP^αIgM). Only unstimulated samples were analysed as the level of antibody levels does not change upon antigen stimulation. The threshold for positivity of 0.29 was determined by computing receiver operating characteristic (ROC) curves.

Ethics. This study was performed according to the Helsinki Declaration as described previously³⁰. The national Research Ethics Committee (Bangladesh Medical Research Council) has approved the study protocol (Ref no. BMRC/NREC/2010-2013/1534).

Participants were informed about the study-objectives, the samples and their right to refuse to take part or withdraw from the study without consequences for their treatment. Written informed consent was obtained before enrolment. All patients received treatment according to national guidelines.

ROC curves. Graphpad Prism version 6.02 for Windows (GraphPad Software, San Diego CA, USA) was used to plot ROC curves and calculate the area under curve (AUC); for IP-10, IL-10, and CCL4 the concentrations (pg/ml) were applied, whereas for anti-PGL-I IgM the OD₄₅₀ corrected for background (ELISA) and ratio value (UCP-LFAs) was used.

Statistical analysis. Differences in cytokine or antibody levels between test groups, as determined with UCP-LFA, were analysed with the One-way ANOVA for non-parametric distribution (Kruskall-Wallis) and Dunn's correction for multiple testing using GraphPad Prism. For IP-10, IL-10 and CCL4 the concentrations (pg/ml) and for anti-PGL-I IgM the UCP-LFA ratio values were utilized. The statistical significance level used was $p \leq 0.05$.

References

1. WHO Global leprosy: update on the 2012 situation. *Wkly. Epidemiol. Rec.* **88**, 365–379 (2013).
2. Lockwood, D. N. & Saunderson, P. Nerve damage in Leprosy: a continuing challenge for scientists, clinicians and service providers. *Int Health* **4**, 77–85 (2012).
3. Scollard, D. M. *et al.* The continuing challenges of leprosy. *Clin. Microbiol. Rev.* **19**, 338–381 (2006).
4. Smith, W. C., van, B. W., Gillis, T., Saunderson, P. & Richardus, J. H. The missing millions: a threat to the elimination of leprosy. *PLoS Negl. Trop. Dis.* **9**, e0003658, doi: 10.1371/journal.pntd.0003658 (2015).
5. Geluk, A. Challenges in immunodiagnostic tests for leprosy. *Expert. Opin. Med. Diagn.* **7**, 265–274 (2013).

6. Xing, Y. *et al.* VNTR typing studies of *Mycobacterium leprae* in China: assessment of methods and stability of markers during treatment. *Lepr. Rev.* **80**, 261–271 (2009).
7. Groothouse, N. A. *et al.* Multiple polymorphic loci for molecular typing of strains of *Mycobacterium leprae*. *J. Clin. Microbiol.* **42**, 1666–1672 (2004).
8. Weng, X., Vander, H. J., Xing, Y., Liu, J. & Vissa, V. Transmission of leprosy in Qiubei County, Yunnan, China: insights from an 8-year molecular epidemiology investigation. *Infect. Genet. Evol.* **11**, 363–374 (2011).
9. Truman, R., Fontes, A. B., De Miranda, A. B., Suffys, P. & Gillis, T. Genotypic variation and stability of four variable-number tandem repeats and their suitability for discriminating strains of *Mycobacterium leprae*. *J. Clin. Microbiol.* **42**, 2558–2565 (2004).
10. Martinez, A. N., Talhari, C., Moraes, M. O. & Talhari, S. PCR-based techniques for leprosy diagnosis: from the laboratory to the clinic. *PLoS. Negl. Trop. Dis.* **8**, e2655, doi: 10.1371/journal.pntd.0002655 (2014).
11. Roset, B. E. *et al.* Leprosy Diagnostic Test Development As a Prerequisite Towards Elimination: Requirements from the User's Perspective. *PLoS. Negl. Trop. Dis.* **10**, e0004331, doi: 10.1371/journal.pntd.0004331 (2016).
12. Matsuoka, M., Kashiwabara, Y. & Namisato, M. A *Mycobacterium leprae* isolate resistant to dapsone, rifampin, ofloxacin and sparflloxacin. *Int. J. Lepr. Other Mycobact. Dis.* **68**, 452–455 (2000).
13. Gupta, U. D., Katoch, K. & Katoch, V. M. Study of rifampicin resistance and comparison of dapsone resistance of *M. leprae* in pre- and post-MDT era. *Indian J. Lepr.* **81**, 131–134 (2009).
14. Ridley, D. S. & Jopling, W. H. Classification of leprosy according to immunity. A five-group system. *Int. J. Lepr. Other Mycobact. Dis.* **34**, 255–273 (1966).
15. Scollard, D. M. Classification of leprosy: a full color spectrum, or black and white? *Int. J. Lepr. Other Mycobact. Dis.* **72**, 166–168 (2004).
16. Geluk, A. *et al.* New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy. *J. Immunol.* **188**, 4782–4791 (2012).
17. Sieling, P. A. *et al.* Immunosuppressive roles for IL-10 and IL-4 in human infection. *In vitro* modulation of T cell responses in leprosy. *J. Immunol.* **150**, 5501–5510 (1993).
18. Pitt, J. M. *et al.* Blockade of IL-10 signaling during bacillus Calmette-Guerin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN- γ and IL-17 responses and increases protection to *Mycobacterium tuberculosis* infection. *J. Immunol.* **189**, 4079–4087 (2012).
19. Khadge, S. *et al.* Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal. *BMC. Infect. Dis.* **15**, 477, doi: 10.1186/s12879-015-1128-0 (2015).
20. Spencer, J. S. *et al.* Analysis of antibody responses to *Mycobacterium leprae* phenolic glycolipid I, lipoarabinomannan, and recombinant proteins to define disease subtype-specific antigenic profiles in leprosy. *Clin. Vaccine Immunol.* **18**, 260–267 (2011).
21. Geluk, A., Duthie, M. S. & Spencer, J. S. Postgenomic *Mycobacterium leprae* antigens for cellular and serological diagnosis of *M. leprae* exposure, infection and leprosy disease. *Lepr. Rev.* **82**, 402–421 (2011).
22. Oskam, L., Slim, E. & Buhrer-Sekula, S. Serology: recent developments, strengths, limitations and prospects: a state of the art overview. *Lepr. Rev.* **74**, 196–205 (2003).
23. Corstjens, P. L. *et al.* A user-friendly, highly sensitive assay to detect the IFN- γ secretion by T cells. *Clin. Biochem.* **41**, 440–444 (2008).
24. Corstjens, P. L. *et al.* Lateral flow assay for simultaneous detection of cellular- and humoral immune responses. *Clin. Biochem.* **44**, 1241–1246 (2011).
25. Zhao, Y. *et al.* Rapid multiplex detection of 10 foodborne pathogens with an up-converting phosphor technology-based 10-channel lateral flow assay. *Sci. Rep.* **6**, 21342, doi: 10.1038/srep21342 (2016).
26. Hua, F. *et al.* Development and evaluation of an up-converting phosphor technology-based lateral flow assay for rapid detection of *Francisella tularensis*. *Sci. Rep.* **5**, 17178, doi: 10.1038/srep17178 (2015).
27. van Dam, G. J. *et al.* A robust dry reagent lateral flow assay for diagnosis of active schistosomiasis by detection of *Schistosoma* circulating anodic antigen. *Exp. Parasitol.* **135**, 274–282 (2013).
28. Corstjens, P. L. *et al.* Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa. *Clin. Biochem.* **49**, 22–31 (2016).
29. Bobosha, K. *et al.* Field-evaluation of a new lateral flow assay for detection of cellular and humoral immunity against *Mycobacterium leprae*. *PLoS. Negl. Trop. Dis.* **8**, e2845, doi: 10.1371/journal.pntd.0002845 (2014).
30. Richardus, R. A. *et al.* The combined effect of chemoprophylaxis with single dose rifampicin and immunoprophylaxis with BCG to prevent leprosy in contacts of newly diagnosed leprosy cases: a cluster randomized controlled trial (MALTALEP study). *BMC. Infect. Dis.* **13**, 456, doi: 10.1186/1471-2334-13-456 (2013).
31. Corstjens, P. L. *et al.* Field-friendly test for monitoring multiple immune response markers during onset and treatment of exacerbated immunity in leprosy. *Clin. Vaccine Immunol.* **23**, 515–519 (2016).
32. Martins, M. V. *et al.* Pathogen-specific epitopes as epidemiological tools for defining the magnitude of *Mycobacterium leprae* transmission in areas endemic for leprosy. *PLoS. Negl. Trop. Dis.* **6**, e1616, doi: 10.1371/journal.pntd.0001616 (2012).
33. Duthie, M. S. *et al.* A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein-glycolipid conjugate. *Diagn. Microbiol. Infect. Dis.* **79**, 233–239 (2014).
34. Duthie, M. S., Orcullo, F. M., Abbelana, J., Maghanoy, A. & Balagon, M. F. Comparative evaluation of antibody detection tests to facilitate the diagnosis of multibacillary leprosy. *Appl. Microbiol. Biotechnol.* **100**, 3267–3275 (2016).
35. Spencer, J. S. *et al.* Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy. *Mem. Inst. Oswaldo Cruz* **107** Suppl 1, 79–89 (2012).
36. Douglas, J. T. *et al.* Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. *Clin. Diagn. Lab Immunol.* **11**, 897–900 (2004).
37. Montoya, D. & Modlin, R. L. Learning from leprosy: insight into the human innate immune response. *Adv. Immunol.* **105**, 1–24 (2010).
38. Keating, S. M. *et al.* The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. *AIDS* **25**, 1823–1832 (2011).
39. Cassatella, M. A. *et al.* Regulated production of the interferon- γ -inducible protein-10 (IP-10) chemokine by human neutrophils. *Eur. J. Immunol.* **27**, 111–115 (1997).
40. Aabye, M. G. *et al.* Potential of interferon- γ -inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients. *Eur. Respir. J.* **36**, 1488–1490 (2010).
41. Berrington, W. R. *et al.* Differential dermal expression of CCL17 and CCL18 in tuberculoid and lepromatous leprosy. *PLoS. Negl. Trop. Dis.* **8**, e3263, doi: 10.1371/journal.pntd.0003263 (2014).
42. Kim, M. H., Choi, Y. W., Choi, H. Y., Myung, K. B. & Cho, S. N. The expression of RAGE and EN-RAGE in leprosy. *Br. J. Dermatol.* **154**, 594–601 (2006).
43. Realegeno, S. *et al.* S100A12 Is Part of the Antimicrobial Network against *Mycobacterium leprae* in Human Macrophages. *PLoS. Pathog.* **12**, e1005705, doi: 10.1371/journal.ppat.1005705 (2016).
44. Zou, K. H., O'Malley, A. J. & Mauri, L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. *Circulation* **115**, 654–657 (2007).

45. Richardus, R. A. *et al.* Clinical manifestations of leprosy after BCG vaccination: an observational study in Bangladesh. *Vaccine* **33**, 1562–1567 (2015).
46. Merle, C. S., Cunha, S. S. & Rodrigues, L. C. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. *Expert. Rev. Vaccines* **9**, 209–222 (2010).
47. Cho, S. N., Yanagihara, D. L., Hunter, S. W., Gelber, R. H. & Brennan, P. J. Serological specificity of phenolic glycolipid I from *Mycobacterium leprae* and use in serodiagnosis of leprosy. *Infect. Immun.* **41**, 1077–1083 (1983).
48. Corstjens, P. *et al.* Use of up-converting phosphor reporters in lateral-flow assays to detect specific nucleic acid sequences: a rapid, sensitive DNA test to identify human papillomavirus type 16 infection. *Clin. Chem.* **47**, 1885–1893 (2001).

Acknowledgements

The authors gratefully acknowledge all patients and blood donors. LUMC, Erasmus MC and TLMI,B are part of the IDEAL (Initiative for Diagnostic and Epidemiological Assays for Leprosy) Consortium. We thank the staff of the Rural Health Program and dr. Ruth Butlin (The Leprosy Mission International Bangladesh, Nilphamari, Bangladesh) for recruitment of study participants and sample collection. Recruitment of the study participants in Bangladesh was supported by grants from the Order of Malta-Grants-for-Leprosy-Research (MALTALEP), the Netherlands Leprosy Relief Foundation (NLR; ILEP#: 7020273 and 703.15.07) together with the German Leprosy and TB Relief Association (GLRA) and the Turing Foundation, the Novartis Foundation and the Leprosy Research Initiative (LRI). Development of the UCP-LFA was supported by the Q.M. Gastmann-Wichers Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

Designed research: A.G. and P.L.A.M.C. Enrolled patients, performed and registered clinical diagnosis: K.A., J.H.R. and R.R. Performed research: A.v.H., C.J.d.D., E.M.T.K.F., L.W., R.R. and S.J.F.v.d.E. Analyzed the data: A.G., A.v.H., E.M.T.K.F., L.W., P.L.A.M.C., R.F. and S.J.F.v.d.E. Wrote the paper: A.G., A.v.H. and P.L.A.M.C. Agree with manuscript results and conclusions: A.G., A.v.H., E.M.T.K.F., R.R., S.J.F.v.d.E., L.W., C.J.d.D., R.F., K.A., J.H.R. and P.L.A.M.C.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: van Hooij, A. *et al.* Quantitative lateral flow strip assays as User-Friendly Tools To Detect Biomarker Profiles For Leprosy. *Sci. Rep.* **6**, 34260; doi: 10.1038/srep34260 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016